Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

Pulmonary administered anticholinergic agents have shown their importance in the chronic obstructive pulmonary disease (COPD) management to reduce morbidity, disability and mortality. To date, the recommended treatment of moderate to severe COPD patients consist in the combination of ß2 agonist and long acting antimuscarinic compounds. There is still a medical need in new product that could exhibit both anti-inflammatory and strong bronchodilation potency. V0162 is a compound with a potent anticholinergic activity.

Secondary PD properties of V0162 could enhance the efficacy of this antimuscarinic compound and could bring new option in the treatment of this life-threatening disease.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pierre Fabre Medicament
• Collaborators: SGS Life Sciences; SGS Life Sciences, a division of SGS Belgium NV

Criteria

Inclusion Criteria Part A:

• Male gender

• Age between 18 to 50 years included,

• 18 ≤ Body Mass Index (BMI) < 30 kg/m²,

• Who had given their written consent for their participation in the study,

• Who, in the judgement of the Investigator, are likely to be compliant during the study,

• Registered with a social security insurance system.

Inclusion Criteria Part B:

• Aged 40 to 65 years-old,

• 18 ≤ BMI < 35 kg/m2,

• Smokers ≥ 10 packs / year,

• Moderate to severe COPD

• Registered with a social security insurance system.

Exclusion Criteria Part A:

• History of asthma or significant respiratory disorder,

• History of allergic rhinitis,

• Upper respiratory tract infection in the last month,

• Blood eosinophil count ≥ 600/μL,

• Epilepsy, narrow angle glaucoma, prostatic hypertrophy or bladder neck obstruction,

• Abnormal spirography,

Exclusion Criteria Part B:

• Respiratory tract infection in the last 6 weeks,

• Asthma or significant respiratory disorder other than COPD,

• Allergic rhinitis,

• Blood eosinophil count ≥ 600/μL,

• Epilepsy, narrow angle glaucoma, moderate to severe prostatic hypertrophy or bladder neckobstruction,

• Myocardial infarction within the previous 6 months, heart failure or serious cardiac arrhythmia,

• Moderate to severe renal impairment,

• Moderate to severe hepatic impairment

• Use of short-acting b-agonist,

• Use of anticholinergics